Aurobindo Pharma Key Ratios

NSE: AUROPHARMA | BSE: 524804

₹1,645.30

up-down-arrow8.30 (0.51%)

As on 28-Aug-2026IST

Market cap

info icon

₹95,225 Cr

Revenue (TTM)

info icon

₹34,935 Cr

P/E Ratio

info icon

25.6

P/B Ratio

info icon

2.4

Div. Yield

info icon

0.2 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 3.35 16.30 9.09 11.11 7.31
EBIT 9.42 16.45 6.91 26.09 4.44
Net Profit 15.05 28.51 11.59 23.14 3.01
EPS 13.13 26.37 9.76 23.83 -6.76
Book Value -- -- 16.04 12.51 11.75
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 21.3813.8514.9614.9715.55
Net Margin info 17.6310.1110.4210.2510.77
Return on equity info 9.9710.2310.389.9311.15
Return on Capital info 11.8012.60--12.7614.39
Return on Assets info 6.577.006.866.647.54
Debt to Equity (x) info ----0.020.200.24
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
--
12.76
14.39
13.76
9.39
Peer Median
--
19.34
21.76
21.89
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

10.38

Lower than Peers by 4.97

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
10.38
9.93
11.15
11.18
7.50
Peer Median
15.35
16.97
17.93
16.42
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

6.86

Lower than Peers by 3.49

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
6.86
6.64
7.54
7.63
5.29
Peer Median
10.35
9.88
12.81
12.32
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

14.96

Lower than Peers by 3.05

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
14.96
14.97
15.55
14.90
9.95
Peer Median
18.01
18.96
18.93
21.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

10.42

Lower than Peers by 4.03

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
10.42
10.25
10.77
10.72
7.67
Peer Median
14.45
13.29
14.94
15.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
--
7.60
8.08
7.85
6.24
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

9.09

Lower than Peers by 2.86

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
9.09
6.08
9.39
16.68
5.97
Peer Median
11.95
12.97
10.90
13.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

6.91

Lower than Peers by 14.69

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
6.91
2.14
14.16
74.67
-24.06
Peer Median
21.60
15.05
15.01
23.50
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

11.59

Lower than Peers by 11.15

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
11.59
0.56
9.93
64.40
-27.18
Peer Median
22.73
11.89
14.80
30.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

9.76

Lower than Peers by 10.27

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
9.76
0.54
10.83
64.62
-27.21
Peer Median
20.03
12.16
14.27
29.02
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
--
16.04
9.42
11.19
9.21
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

0.02

Higher than Peers by 0.02

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
0.02
0.20
0.24
0.21
0.18
Peer Median
0.00
0.05
0.06
0.03
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
--
0.16
0.17
0.14
0.16
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.81

Lower than Peers by 0.27

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
1.81
1.81
1.85
1.95
1.87
Peer Median
2.08
1.93
1.90
2.23
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.15

Lower than Peers by 0.39

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
1.15
1.15
1.13
1.14
1.13
Peer Median
1.54
1.52
1.46
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

14.98

Lower than Peers by 4.40

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
14.98
14.31
12.08
16.12
19.60
Peer Median
19.38
19.95
24.96
45.29
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

20.31

Lower than Peers by 1.07

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
20.31
21.08
18.11
16.61
17.97
Peer Median
21.38
19.87
21.77
20.10
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.65

Lower than Peers by 0.08

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
0.65
1.32
1.38
1.44
1.40
Peer Median
0.72
0.77
0.76
0.81
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
--
33.71
30.33
28.34
30.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
--
59.32
58.44
55.92
57.65
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
--
148.20
135.14
133.88
117.74
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
--
-55.17
-46.37
-49.62
-29.67
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

25.65

Lower than Peers by 8.38

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
25.65
21.60
19.32
20.12
15.75
Peer Median
34.03
34.29
26.81
39.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

2.45

Lower than Peers by 2.37

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
2.45
2.00
2.06
2.14
1.13
Peer Median
4.82
5.12
4.65
6.11
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.24

Lower than Peers by 0.26

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
0.24
0.31
--
0.41
0.58
Peer Median
0.51
0.51
0.61
0.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

11.97

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
11.97
10.02
9.31
9.98
7.27
Peer Median
--
30.60
27.02
34.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

95,225

Higher than Peers by 75,902

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Aurobindo Pharma
95,225
75,689
67,356
63,830
30,348
Peer Median
19,323
17,990
20,914
25,297
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...